ALX Oncology Holdings (ALXO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on ALX Oncology Holdings (ALXO) is Neutral.

The composite score behind that read is -0.08, weighing +0.17 of bullish evidence against -0.30 bearish.

ALX Oncology Holdings last closed at $1.25, +5.93% on the session.

Against the IVW growth benchmark the position is +5.13% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

17 graded predictions for ALXO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks ALX Oncology Holdings in the 12th percentile on return on equity, where 100 is best.

ALX Oncology Holdings is classified under Health Care / Biotechnology, with a market capitalisation of $163.17M.

StockMap tracks ALX Oncology Holdings as the 256th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite ALX Oncology Holdings ranks 188th of 381 in the group, against a group median of -0.08.